Sunitinib in the management of gastrointestinal stromal tumours (GISTs)

European Journal of Surgical Oncology

Volumn 34, Issue 8, 2008, Pages 844-850

  Hopkins, T G ^a   Marples, M ^b   Stark, D ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Gastrointestinal stromal tumour; GIST; Phase III trial; Protein kinase inhibitors; Sunitinib

Indexed keywords

CARBAMAZEPINE; CD135 ANTIGEN; CLARITHROMYCIN; DEXAMETHASONE; HYPERICUM PERFORATUM EXTRACT; IMATINIB; KETOCONAZOLE; PHENYTOIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RIFAMPICIN; RITONAVIR; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; BLEEDING; BLISTER; CLINICAL TRIAL; DEPIGMENTATION; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRY SKIN; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GRAPEFRUIT; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HISTOLOGY; HUMAN; HYPERKERATOSIS; HYPERTENSION; HYPOTHYROIDISM; INCIDENCE; MEDICAL LITERATURE; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; SKIN MANIFESTATION; SURVIVAL TIME; VOMITING;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PYRROLES; TREATMENT OUTCOME;

EID: 46749092165     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.10.011     Document Type: Review

References (52)

1. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1 (2002) 493-502
2. Andersson L.C. Significance of tyrosine kinases in cancer: overview. Eur J Cancer 38 Suppl. 5 (2002) S2
3. Tannock I. The basic science of oncology (2005), McGraw-Hill Medical Pub. Division, New York; London p. 341-7, 64-72
4. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
5. Snyder M.A., Bishop J.M., McGrath J.P., and Levinson A.D. A mutation at the ATP-binding site of pp60v-src abolishes kinase activity, transformation, and tumorigenicity. Mol Cell Biol 5 (1985) 1772-1779
6. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
7. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 312 (2006) 1171-1175
8. Nowain A., Bhakta H., Pais S., Kanel G., and Verma S. Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol 20 (2005) 818-824
9. Trent J.C., and Benjamin R.S. New developments in gastrointestinal stromal tumor. Curr Opin Oncol 18 (2006) 386-395
10. Tornillo L., and Terracciano L.M. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 59 (2006) 557-563
11. Emory T.S., Sobin L.H., Lukes L., Lee D.H., and O'Leary T.J. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23 (1999) 82-87
12. Heinrich M.C., Rubin B.P., Longley B.J., and Fletcher J.A. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33 (2002) 484-495
13. Dematteo R.P., Heinrich M.C., El-Rifai W.M., and Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33 (2002) 466-477
14. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
15. Ng E.H., Pollock R.E., Munsell M.F., Atkinson E.N., and Romsdahl M.M. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215 (1992) 68-77
16. Burkill G.J., Badran M., Al-Muderis O., et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 226 (2003) 527-532
17. Nakamura N., Yamamoto H., Yao T., et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 36 (2005) 828-837
18. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., and Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
19. Mudan S.S., Conlon K.C., Woodruff J.M., Lewis J.J., and Brennan M.F. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 88 (2000) 66-74
20. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
21. Pearson M.A., and Fabbro D. Targeting protein kinases in cancer therapy: a success?. Expert Rev Anticancer Ther 4 (2004) 1113-1124
22. Buchdunger E., O'Reilly T., and Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 38 Suppl. 5 (2002) S28-S36
23. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 368 (2006) 1303-1304
24. NICE. Technology review: imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours. 2004.
25. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 (2006) 4764-4774
26. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 (2006) 1093-1103
27. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
28. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
29. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60 (2000) 4152-4160
30. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., and Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2 (2003) 471-478
31. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
32. Sun L., Liang C., Shirazian S., et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46 (2003) 1116-1119
33. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
34. van den Abbeele A., Melenevsky D., de Vries J., Manola P., Dileo R., and Demetri G.D. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). J Clin Oncol (2005) ASCO Annual Meeting Proceedings. Vol. 23, No. 16S, Part I of II (June 1 Supplement), 2005: 9006
35. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
36. Maki R., Fletcher J., Heinrich M., et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (2005) ASCO Annual Meeting Proceedings. Vol. 23, No. 16S, Part I of II (June 1 Supplement), 2005: 9011
37. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
38. Demetri G., van Oosterom A., and Casali P. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. J Clin Oncol (2005) ASCO Annual Meeting Proceedings. Vol. 23, No. 16S, Part I of II (June 1 Supplement); 4000: 2005
39. Blay J., Le Cesne A., Ray-Coquard R., et al. Prospective multicentric randomized phase III study of Imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French sarcoma group. J Clin Oncol 25 (2007) 1107-1113
40. NIH Clinical Trials Database. Available from: www.clinicaltrials.gov/ct.
41. Casali P., Garrett C., and Blackstein M. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol (2006) ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S, 2006: 9513
42. George S., Blay J., Casali P., et al. Continuous daily dosing of sunitinib malate compares favorably with intermittent dosing in patients with advanced GIST. J Clin Oncol (2007) ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007
43. FDA Labelling Instructions. Available from: http://www.fda.gov/cder/foi/label/2006/021968lbl.pdf.
44. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
45. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 (2006) 660-664
46. Wood L.S. Managing side effects of sorafenib and sunitinib. Community Oncol 3 (2006) 558-562
47. Scottish Medicines Consortium. 'Sunitinib 50 mg capsule (Sutent) No. 275/06'. Available from: http://www.scottishmedicines.org.uk/smc/files/.
48. Prenen H., Cools J., Mentens N., et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12 (2006) 2622-2627
49. Wardelmann E., Merkelbach-Bruse S., Pauls K., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12 (2006) 1743-1749
50. Wardelmann E., Biermann K., and Merkelbach-Bruse B. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin Cancer Res 12 (2006) 6206
51. Loughrey M.B., Waring P.M., Dobrovic A., Demetri G., Kovalenko S., and McArthur G. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin Cancer Res 12 (2006) 6205-6206 author reply 6-7
52. Heinrich M., Corless C., Liegl B., et al. Mechanisms of Sunitinib Malate resistance in gastrointestinal stromal tumors. J Clin Oncol (2007) ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007